NBTX

Nanobiotix S.A.
CAPPED RATING

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A. (NBTX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C-
Factor Score 2.1 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -192.3
EV / EBITDA -54.9
Rev Growth YoY -79.2%
Gross Margin N/M
Price Return 3M -15.8%
Price Return 12M 54.2%
Catalyst Signal 0.00
Market Cap $1.6B
TTM Revenue $11.5M
Price / Sales 142.8
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C- (2.1) C+ (2.7) B (3.3) D+ (1.6) C+ (2.6) C (2.5)
2026-11-06 C (2.2) C+ (2.7) B (3.3) C- (1.9) C+ (2.7) C+ (2.5)
2026-10-30 C- (2.1) C+ (2.6) B (3.3) C+ (2.6) C+ (2.7) C+ (2.6)
2026-10-23 C (2.2) C+ (2.6) B (3.2) C+ (2.5) C+ (2.6) C+ (2.6)
2026-10-16 C (2.4) C+ (2.6) B (3.2) C (2.2) C+ (2.6) C+ (2.6)
Page 1 of 3